These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 15184993

  • 1. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP, Epelman S, Bush DA.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [Abstract] [Full Text] [Related]

  • 2. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [Abstract] [Full Text] [Related]

  • 3. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep 01; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 4. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct 01; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I, Keefe D, Myers M, Caruso D.
    Chemotherapy; 2005 May 01; 51(2-3):142-6. PubMed ID: 15886474
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT.
    J Clin Oncol; 1998 Feb 01; 16(2):616-21. PubMed ID: 9469350
    [Abstract] [Full Text] [Related]

  • 7. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP, Pratt CB, Meyer WH, Wright RK, Dodge RK, Viar MJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C, Küpfer A, Schefer H, Cerny T.
    Drug Metab Dispos; 1998 Sep 15; 26(9):883-90. PubMed ID: 9733667
    [Abstract] [Full Text] [Related]

  • 12. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R.
    Clin Cancer Res; 2000 Apr 15; 6(4):1314-21. PubMed ID: 10778956
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC, Solidoro A, Casanova L, Vallejos C, Rodriguez W.
    J Exp Ther Oncol; 1996 Mar 15; 1(2):84-7. PubMed ID: 9414391
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M.
    Gynecol Oncol; 2000 Aug 15; 78(2):221-7. PubMed ID: 10926807
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Aug 15; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 17. [Ifosfamide induced encephalopathy: 15 observations].
    Dufour C, Grill J, Sabouraud P, Behar C, Munzer M, Motte J, Oberlin O, Paci A, Hartmann O.
    Arch Pediatr; 2006 Feb 15; 13(2):140-5. PubMed ID: 16364615
    [Abstract] [Full Text] [Related]

  • 18. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G, Clocchiatti L, Sacco C, Pella N, Bearz A, Mantero J, Pastorelli D, Salmaso F, Zustovich F.
    Oncology; 2003 Feb 15; 65 Suppl 2():31-6. PubMed ID: 14586144
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.
    J Clin Pharmacol; 1999 May 15; 39(5):454-61. PubMed ID: 10234592
    [Abstract] [Full Text] [Related]

  • 20. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1996 Jun 15; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.